Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xtant Medical Holdings (XTNT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Xtant Medical Holdings (XTNT) over the last 17 years, with Q3 2025 value amounting to 7.64%.

  • Xtant Medical Holdings' EBITDA Margin rose 211600.0% to 7.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.77%, marking a year-over-year increase of 170600.0%. This contributed to the annual value of 10.3% for FY2024, which is 8300.0% up from last year.
  • Per Xtant Medical Holdings' latest filing, its EBITDA Margin stood at 7.64% for Q3 2025, which was up 211600.0% from 13.06% recorded in Q2 2025.
  • Xtant Medical Holdings' EBITDA Margin's 5-year high stood at 13.06% during Q2 2025, with a 5-year trough of 14.13% in Q1 2022.
  • Its 5-year average for EBITDA Margin is 7.11%, with a median of 9.84% in 2024.
  • As far as peak fluctuations go, Xtant Medical Holdings' EBITDA Margin plummeted by -159100bps in 2021, and later skyrocketed by 229000bps in 2025.
  • Over the past 5 years, Xtant Medical Holdings' EBITDA Margin (Quarter) stood at 13.68% in 2021, then grew by 17bps to 11.29% in 2022, then decreased by -20bps to 13.54% in 2023, then skyrocketed by 56bps to 5.97% in 2024, then surged by 228bps to 7.64% in 2025.
  • Its EBITDA Margin stands at 7.64% for Q3 2025, versus 13.06% for Q2 2025 and 3.23% for Q1 2025.